De l'intérêt d'être agile - ACHAT - OC 4€ (vs 4,2€)
Les résultats 2016 sont marqués par une bonne maitrise des charges et une stabilité de la perte nette. La consommation de cash a baissé (-0,6m€) et la société a eu accès à de nouveaux financements (+2,9m€ d’avances remboursables). La nouvelle focalisation stratégique devrait accélérer les premiers revenus mais monopoliser définitivement les ressources de la société, ce qui ne permettra pas de reprise du programme Deinol à CT. Nous excluons ce dernier de notre valorisation, tablons sur 3 molécules du programme Deinochem et la réussite du candidat antibiotique. Notre nouvelle valorisation ressort à 4,0€ (vs 4,2€ préc), nous conservons notre opinion ACHAT.Deinove SA is a biotechnology company dedicated to the discovery, development and production of compounds based on the use of rare bacterial genus that present an interest to the health, nutrition and cosmetics sectors.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.